A365270 Stock Overview
Curacle Co., Ltd., a bio-venture business, engages in the research and development of drugs for diseases caused by aging process and damage to blood vessels. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
curacle co.,ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩6,150.00 |
| 52 Week High | ₩21,350.00 |
| 52 Week Low | ₩4,900.00 |
| Beta | 1.51 |
| 1 Month Change | 1.15% |
| 3 Month Change | 3.02% |
| 1 Year Change | -43.68% |
| 3 Year Change | -72.67% |
| 5 Year Change | n/a |
| Change since IPO | -79.93% |
Recent News & Updates
Is curacleltd (KOSDAQ:365270) Using Too Much Debt?
Nov 01
curacleltd (KOSDAQ:365270) Has Debt But No Earnings; Should You Worry?
Jun 26Is Curacle (KOSDAQ:365270) Using Too Much Debt?
Feb 27Shareholder Returns
| A365270 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -1.9% | -1.2% | -0.9% |
| 1Y | -43.7% | 16.3% | -9.0% |
Return vs Industry: A365270 underperformed the KR Biotechs industry which returned 16.1% over the past year.
Return vs Market: A365270 underperformed the KR Market which returned -9% over the past year.
Price Volatility
| A365270 volatility | |
|---|---|
| A365270 Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A365270 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A365270's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Jaehyeon Yoo | curacle.com |
Curacle Co., Ltd., a bio-venture business, engages in the research and development of drugs for diseases caused by aging process and damage to blood vessels. Its products cover age-related vascular diseases, intractable metabolic diseases, and cancer targeting/immunotherapy. The company’s products in pipeline include CU06, which covers treatment and medical indications, such as diabetic macular edema/retinopathy, acute respiratory distress syndrome, myocardial infarction, stroke treatment, concomitantly used with immunotherapy, inflammatory bowel disease treatment, and hereditary angioedema; CU03, which is in Phase 2a clinical trial study for the treatment of age-related macular degeneration; and CU01, a diabetic nephropathy medicine that completed Phase 2a clinical trial.
curacle co.,ltd. Fundamentals Summary
| A365270 fundamental statistics | |
|---|---|
| Market cap | ₩85.32b |
| Earnings (TTM) | -₩16.49b |
| Revenue (TTM) | ₩1.77b |
48.1x
P/S Ratio-5.2x
P/E RatioIs A365270 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A365270 income statement (TTM) | |
|---|---|
| Revenue | ₩1.77b |
| Cost of Revenue | ₩15.26m |
| Gross Profit | ₩1.76b |
| Other Expenses | ₩18.25b |
| Earnings | -₩16.49b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.19k |
| Gross Margin | 99.14% |
| Net Profit Margin | -930.48% |
| Debt/Equity Ratio | 62.2% |
How did A365270 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 07:34 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
curacle co.,ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|